David Fandrei

6PUBLICATIONS
118CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 12, 2026
Outcomes of CAR T-cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

|Mar 31, 2025
Clonal Evolution of PPM1D Mutations in the Spectrum of Myeloid Disorders.

David Fandrei, Jean Pegliasco, Florence Pasquier

|Feb 21, 2025
Multiomic profiling of T cell lymphoma after therapy with anti-BCMA CAR T cells and GPRC5D-directed bispecific antibody.

Till Braun, Michael Rade, Maximilian Merz

|Dec 05, 2024
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.

Maximilian Merz, Danai Dima, Hamza Hashmi

|Oct 23, 2024
Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma.

David Fandrei, Sabine Seiffert, Michael Rade

Pageof 1

Frequent Collaborators

4 joint publications

Maximilian Merz

3 joint publications

Vladan Vucinic

3 joint publications

Nico Gagelmann

2 joint publications

Friederike Schmitz